Is Avalon Labs a Good Investment?

C-Value
C+Risk
|Lending
Loading price data...
TVL$3M
FDV$28M
TVL/FDV0.11x
Risk GradeC+
Value GradeC-

Value Accrual: Does the Avalon Labs Token Capture Value?

Avalon Labs scores C- on Hindenrank's value accrual framework (42/100), indicating average value capture — some strengths offset by weaknesses in fee distribution or sustainability. Fee capture scores 11/25 — moderate, with some fees reaching token holders but room for improvement. Token distribution is rated 0/25 (highly concentrated, posing material governance and sell-pressure risks), and emission sustainability sits at 20/25. The competitive moat dimension scores 11/25.

Scored as: Business
Fee Capture
11/25
Token Distribution
0/25
Emission Sustainability
20/25
Competitive Moat
11/25

Protocol Health: Is Avalon Labs Still Growing?

Avalon Labs's vitality risk score is 7/10 on Hindenrank's rubric (lower is healthier). This raises concerns about protocol vitality — Avalon Labs shows signs of declining activity, stagnant or falling TVL, or reduced developer engagement. Investors should monitor whether this trend reverses before increasing exposure.

Risk-Adjusted View: Is the Upside Worth the Risk?

Risk-Adjusted Position

Neutral
High Value
Medium Value
Low Value
High Risk
High Risk Play
Risky
Avoid
Medium Risk
Promising
Avalon Labs
Weak
Low Risk
Blue Chip
Safe but Stale
Dead Money
See all Neutral protocols →

Avalon Labs sits in the Neutral zone — average on both risk (C+) and value (C-). There is no strong reason to overweight or avoid the token at current levels. Monitor for catalysts that could shift the balance in either direction.

Risk Context

Avalon Labs carries a risk grade of C+ (42/100), classified as elevated risk — multiple novel mechanisms and notable interaction risks. While no critical-severity interactions were identified, 1 high-severity interaction warrant attention. The primary risk factor is: Concentrated exposure to Sonic L1, a new chain with limited battle-testing. A critical bug in Sonic's EVM implementation could compromise all lending pools.

Read our full safety analysis →

Should you buy Avalon Labs?

Avalon Labs scores C- on Hindenrank's value accrual framework, placing it among the average Lending protocols. Fee capture scores 11/25 — moderate, with some fees reaching token holders but room for improvement. Token distribution is highly concentrated, posing material governance and sell-pressure risks, and emission sustainability sits at 20/25. On the risk side, Avalon Labs carries a C+ grade (42/100), which is elevated risk — multiple novel mechanisms and notable interaction risks. The combined risk-value position places Avalon Labs in the Neutral quadrant.

Avalon Labs investment outlook for 2026

With $3M in total value locked and FDV of $28M, giving a TVL/FDV ratio of 0.11, Avalon Labs's fundamentals do not strongly support the current valuation from a usage perspective. The competitive moat dimension scores 11/25, suggesting limited moat, leaving the protocol vulnerable to competitive pressure.Investors should weigh these fundamentals alongside market conditions and their own risk tolerance.

This analysis is based on cryptoeconomic fundamentals, not price prediction. It is not financial advice. Full methodology

Weekly Commentary

Pro

Week of March 3, 2026

Avalon Labs sits in no-man's-land with a C+ risk grade and C- value score — neither safe enough to trust nor cheap enough to justify the exposure. At just $3M TVL, this is a micro-scale lending protocol carrying mid-tier risk without the token economics to compensate holders for it. The neutral quadrant placement is generous; there's no clear catalyst to move either score in the right direction.

Related Lending Investment Analyses

Related Lending Safety Analyses

Investment analysis uses Hindenrank's value accrual framework across four dimensions: fee capture, token distribution, emission sustainability, and competitive moat. Higher score = better value accrual. Combined with our eight-dimension risk rubric for risk-adjusted positioning. This is not financial advice.